[
  {
    "question": "Patient had recurrent nocturan seizure with hypermotor features, also hx of asymmetric posturing and ? Strange feelinh, and brief loss of awareness where is the focus",
    "option_a": "Orbitofrontal",
    "option_b": "SMA",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "This question describes a patient with recurrent nocturnal seizures that are hypermotor in nature, accompanied by a history of asymmetric posturing, a strange feeling (likely an aura), and brief loss of awareness. These features are most consistent with a focal seizure originating from the frontal lobe. Among the frontal subregions, the supplementary motor area (SMA) is classically implicated in generating hypermotor seizures, especially those that occur during sleep. The SMA is involved in planning and initiating voluntary movements. When epileptogenic discharges arise from this area, they trigger abnormal motor output that often manifests as abrupt, hyperkinetic, or asymmetric movements. The propagation of these discharges to adjacent motor regions and subcortical structures contributes to the varied motor manifestations. Recent studies using advanced neuroimaging and electrophysiological modalities have confirmed the role of the SMA in producing focal seizure semiology with hypermotor features. Clinically, seizures originating from the SMA often occur during sleep, leading to dramatic motor episodes that may include asymmetric movements or posturing. The presence of a peculiar aura (the 'strange feeling') may represent early sensory phenomena before the motor spread. Brief impairment of awareness is consistent with focal impaired awareness seizures that can emerge from frontal lobe foci. The diagnosis is typically supported by video EEG monitoring, preferably including sleep recordings, as well as high-resolution MRI to detect any structural abnormalities. Differential diagnoses include temporal lobe seizures, which may also present with auras but usually have more prominent autonomic or emotional symptoms, and nocturnal paroxysmal events like parasomnias. Differentiation relies on detailed clinical history, ictal semiology, and corroborative electroencephalographic findings. First-line management involves initiating an appropriate antiepileptic drug (AED) regimen, with agents such as carbamazepine, lamotrigine, or levetiracetam considered based on patient comorbidities and potential side effects. For patients with drug-resistant seizures, surgical evaluation including invasive monitoring may be warranted. In pregnant or lactating patients, AED selection must consider teratogenic potential \u2013 options like lamotrigine and levetiracetam are favored due to their safer profiles. Close follow-up with neurology is recommended to adjust therapy based on seizure control and side effects. Option A (Orbitofrontal) is not the best answer because while orbitofrontal seizures can present with bizarre behaviors and even autonomic symptoms, they more frequently involve olfactory or gustatory hallucinations rather than the prominent hypermotor phenomena and asymmetric posturing described. Option B (SMA) correctly corresponds to the clinical picture described. Options C and D are not provided. 1. Frontal lobe seizures, particularly those from the SMA, often occur during sleep and involve hypermotor manifestations. 2. Auras such as a 'strange feeling' aid in localizing the focus of seizure onset. 3. Early identification and treatment of focal epilepsies can improve long-term outcomes. Recent research emphasizes the utility of video EEG and advanced imaging (such as functional MRI and PET) in localizing epileptogenic zones in frontal lobe epilepsy. Latest guidelines underscore a tailored AED approach with special considerations for women of childbearing age to reduce teratogenic risks.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Laryngeal discomfort, tonic posturing",
    "option_a": "Insular seizure",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This question highlights a scenario where the patient experiences laryngeal discomfort along with tonic posturing. Such symptoms are recognized as potential manifestations of insular seizures, as the insular cortex is deeply involved in processing visceral and autonomic sensory information. The insular cortex plays a crucial role in integrating sensory, autonomic, and limbic functions. Epileptogenic activity in this region can produce a variety of symptoms including laryngeal discomfort (which might be interpreted as throat tightness or pain) and associated motor phenomena like tonic posturing. The spread of epileptiform discharges from the insula to adjacent motor areas can further explain the motor findings. Patients with insular seizures may report unusual visceral sensations such as laryngeal discomfort, often accompanied by motor manifestations. These seizures can be mistaken for other disorders (e.g., cardiac or gastrointestinal issues), making detailed clinical history and appropriate testing critical. Diagnosis is supported by EEG, though scalp EEG may have limited sensitivity because of the insula's deep location. Advanced imaging modalities such as MRI and, in some cases, intracranial EEG monitoring may be necessary to precisely localize the focus. Differential diagnoses include temporal lobe epilepsy (which more commonly presents with psychic or gustatory phenomena) and other focal epilepsies affecting the opercular or perisylvian regions. Management involves the initiation of appropriate antiepileptic drugs. First-line AEDs such as levetiracetam or lamotrigine are considered, along with careful monitoring of treatment response. For individuals who are pregnant or lactating, medications with a lower teratogenic profile such as lamotrigine and levetiracetam are preferred. In refractory cases, surgical evaluation for insular resection may be considered. Option A (Insular seizure) is the correct answer as insular seizures are known to produce laryngeal discomfort and can be associated with tonic posturing. The other options are absent, so Option A stands as the best and only provided answer. 1. Insular seizures may present with atypical manifestations such as throat discomfort and should be differentiated from more common temporal lobe seizures. 2. Deep-seated epileptogenic foci, such as the insula, may require advanced imaging and sometimes invasive EEG monitoring for accurate localization. Recent literature supports the notion that insular epilepsy can be under-recognized due to its atypical presentation. Newer diagnostic techniques, including high-field MRI and advanced electrophysiologic mapping, have improved the identification and treatment planning for this entity.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Patient had 3 attacks of unprovoked seizures with normal labs what to do",
    "option_a": "Start AED, MRI, EEG then to be seen in the clinic.",
    "option_b": "EEG & MRI",
    "option_c": "Start AED & discharge",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "The patient has experienced three attacks of unprovoked seizures with normal laboratory investigations, fitting the clinical criteria for epilepsy. By current definitions, the occurrence of at least two unprovoked seizures establishes an epilepsy diagnosis, thus justifying both further investigation and treatment. Unprovoked seizures suggest an intrinsic abnormality in neuronal excitability, which may be due to an underlying structural, genetic, or idiopathic cause. Although the routine labs are normal, the epileptogenic process can be due to subtle changes not detected on basic evaluations, necessitating further neurophysiological and radiological assessments. Recurrent unprovoked seizures increase the risk of subsequent seizures, potential injury, and adverse psychosocial consequences. The initiation of treatment along with detailed investigation is essential to localize the focus, classify the epilepsy, and guide appropriate management. The mainstay of diagnostic evaluation includes an EEG to assess for epileptiform discharges and an MRI to detect any structural lesions or subtle cortical dysplasias. Differential diagnoses include psychogenic nonepileptic seizures and syncope, which are differentiated by careful history, witness accounts, and targeted investigations. Based on current guidelines, after confirming a diagnosis of epilepsy (especially after three unprovoked seizures), it is appropriate to start an antiepileptic drug (AED). First-line AEDs such as lamotrigine, levetiracetam, or carbamazepine are typically preferred. In pregnant or lactating patients, the teratogenic potential of AEDs must be considered \u2013 lamotrigine and levetiracetam are generally considered safer. Additionally, comprehensive evaluation with EEG and MRI is integral for establishing the seizure type and potential etiology, thereby guiding further treatment. Option A, which recommends starting AED therapy and ordering an MRI and EEG before clinic follow-up, is the most comprehensive and is correct. Option B (EEG & MRI) omits immediate initiation of treatment despite a clear clinical diagnosis. Option C (Start AED & discharge) fails to include important diagnostic evaluation, which is essential for tailoring therapy and understanding etiology. 1. Two or more unprovoked seizures are sufficient to diagnose epilepsy, warranting prompt initiation of AED therapy. 2. A comprehensive workup with EEG and MRI plays a crucial role in localizing the epileptogenic focus and guiding management. 3. Early treatment can reduce future seizure risk and improve patient outcomes. Recent guidelines from the International League Against Epilepsy (ILAE) support early initiation of AED therapy in newly diagnosed epilepsy to reduce morbidity. Emerging evidence also emphasizes the importance of tailored imaging protocols and EEG monitoring in optimizing treatment strategies.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Focal seizure I think what\u2019s favor good prognosis",
    "option_a": "One seizure type",
    "option_b": "Long duration of disease activity",
    "option_c": "MRI lesion of nonspecific WM changes",
    "option_d": "Short duration of remission",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This question addresses prognostic factors in focal epilepsy. A favorable prognosis is generally associated with a simpler seizure profile, and having only one seizure type implies a more localized and less complex epileptogenic network. When epilepsy is characterized by a single type of seizure, it usually suggests that the epileptogenic zone is well localized. A localized focus is more likely to respond to treatment and may even be amenable to surgical intervention if needed. In contrast, multiple seizure types could indicate a more widespread or multifocal involvement, making seizure control more challenging. Patients with only one seizure type typically have a more consistent clinical presentation and are more likely to achieve good control with mono-therapy. In contrast, a long duration of disease, multiple seizure types, or nonspecific white matter changes on MRI (which may not correlate with a well-defined lesion) tend to be associated with a poorer prognosis. Diagnosis is made clinically and corroborated with EEG and MRI findings. Differential considerations involve distinguishing between focal epilepsy with a single seizure type versus multifocal or generalized epilepsy, where a broader clinical spectrum and multiple seizure types are observed. Management is tailored according to seizure type and frequency. For patients with a single seizure type, first-line monotherapy with common AEDs (e.g., carbamazepine, lamotrigine) is usually sufficient. In pregnant or lactating women, AEDs with a safer profile (like lamotrigine or levetiracetam) are preferred. Long-term follow-up is necessary to monitor efficacy, side effects, and potential adjustments in therapy. Option A (One seizure type) is the correct answer because it implies a more localized, homogeneous epileptic process that is generally easier to control. Option B (Long duration of disease activity) is typically associated with a more intractable course. Option C (MRI lesion of nonspecific WM changes) does not necessarily correlate with a favorable outcome and may represent incidental findings. Option D (Short duration of remission) suggests unstable control and is linked with poorer prognosis. 1. A single, well-defined seizure type is a positive prognostic marker in focal epilepsy. 2. Homogeneity in seizure presentation often predicts better response to monotherapy. 3. Regular follow-up and tailored AED choices are key to optimizing outcomes. Current research underscores the importance of seizure type homogeneity in predicting treatment response and long-term seizure control. Recent guideline updates continue to recommend individualized treatment plans based on detailed clinical, EEG, and imaging assessments.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "feature of right temporal epilepsy?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "2",
    "subspecialty": "Epilepsy",
    "explanation": "Temporal lobe epilepsy is known for a variety of ictal manifestations. Seizures arising from the temporal lobe may include automatisms (like repetitive nose\u2010wiping) as well as motor phenomena when the seizure activity propagates to adjacent motor areas. The key in this question is the difference between a non\u2010localizing automatism and a motor sign that indicates propagation. Seizure discharges in the temporal lobe (especially on the right side) can spread to the motor cortex. Automatisms \u2013 such as ipsilateral nose\u2010wiping \u2013 are generated by complex limbic and behavioral networks and typically do not indicate direct motor involvement. In contrast, a phenomenon like the 'figure\u2010of\u20104' posture represents a patterned, contralateral motor response produced when the seizure discharge reaches motor regions, specifically resulting in an asymmetric posturing (extension of one limb with simultaneous contrasting movement of the other). Patients with temporal lobe seizures often exhibit both non\u2010specific automatisms and, when seizures spread, lateralizing motor phenomena. The figure\u2010of\u20104 sign in a right temporal seizure reflects propagation and involvement of the contralateral (left) motor pathways. Recognizing which signs are merely automatisms and which actually indicate spread is crucial for localizing the epileptogenic zone. Diagnosis is based on a detailed clinical history and video-EEG monitoring. Differential diagnoses include frontal lobe epilepsy (which might produce hyperkinetic or bizarre motor activities) and psychogenic nonepileptic events. The precise semiological description helps differentiate temporal lobe seizures from these other conditions. Treatment is generally initiated with antiepileptic drugs such as carbamazepine, lamotrigine, or levetiracetam. For patients with drug\u2010refractory seizures, surgical evaluation (e.g., anterior temporal lobectomy) may be considered. In pregnancy and lactation, drug selection requires balancing efficacy with teratogenic risk and pharmacokinetics changes; medications with lower teratogenicity profiles and close monitoring are preferred. Option 1 (Ipsilateral nose-wiping) represents an automatism commonly seen in temporal lobe seizures but does not reliably indicate seizure spread. Option 2 (Figure-of-4 left limb extension) is a classic sign of contralateral motor involvement due to seizure spread from the right temporal focus. Thus, Option 2 is the correct and best localizing sign. 1. Automatisms such as nose-wiping are common in temporal lobe seizures but are not lateralizing. 2. Contralateral motor phenomena (such as the figure-of-4 posture) are strong indicators of propagation to motor cortex from a temporal lobe focus. Recent literature emphasizes the importance of detailed ictal semiology, supported by video EEG and high-resolution imaging, to accurately localize the seizure focus. Studies reinforce that lateralizing motor signs are reliable indicators of seizure spread, which is critical in planning both pharmacologic and surgical management.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "patient ith seizure and AED, she developed Aplastic anemia.\nWhat is the medication?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Antiepileptic drugs (AEDs) are associated with a spectrum of side effects; some have well-established hematological toxicities. Understanding which AED is most notorious for causing aplastic anemia is critical when evaluating adverse events. Carbamazepine is known to induce aplastic anemia via an idiosyncratic, immune-mediated reaction that leads to bone marrow suppression. Its reactive metabolites can trigger hypersensitivity responses in susceptible individuals. Although other AEDs like valproate and felbamate have their own adverse hematological profiles, the classic association of drug-induced aplastic anemia is with carbamazepine. A patient developing aplastic anemia while on AED therapy may present with signs such as fatigue, pallor, bleeding tendencies, and infections due to pancytopenia. Recognizing the causative agent is essential in preventing further marrow suppression and complications. Diagnosis involves correlating the clinical time course with medication use, performing blood tests (complete blood count with differential), and possibly a bone marrow biopsy. Differential diagnoses include aplastic anemia from other causes such as autoimmune disorders, other drug exposures, or viral infections. Management begins with immediate discontinuation of the offending agent. Supportive care including blood transfusions and supportive measures may be necessary. In severe cases, immunosuppressive therapy or bone marrow transplantation might be required. In pregnancy and lactation, careful weighing of seizure control versus hematologic risk is essential, with alternative safer medications considered when possible. Option 1: Valproate is more commonly associated with thrombocytopenia than aplastic anemia. Option 2: Carbamazepine has the most documented association with aplastic anemia, making it the correct choice. Option 3: Felbamate, despite carrying a risk, is far less commonly associated with aplastic anemia and is used less frequently due to its overall risk profile. 1. Always monitor blood counts in patients on carbamazepine due to its potential for serious blood dyscrasias. 2. Distinguishing among AED adverse effects is key, as similar drugs can have markedly different hematologic risk profiles. Recent reviews and guideline updates continue to underscore carbamazepine\u2019s risk for severe hematologic complications, prompting routine monitoring of blood indices, especially in the early stages of therapy.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "long senario about nocturnal epilepsy with brief, abrupt onset less than 1 min, hyperkinetic Asymmetrical Extention of lim And also mention in the q pt have morning seizure with (aura)\nWhat is the localization?",
    "option_a": "Frontal operculum seizures are usually characterized by speech arrest and orofacial automatisms, not the hyperkinetic asymmetric limb extension described. Option B: Dorsolateral frontal seizures tend to produce more complex, less stereotyped motor behaviors. Option C: Mesial temporal lobe seizures typically present with auras and automatisms rather than abrupt hyperkinetic movement. Option D: The Supplementary Motor Area (SMA) best explains the brief, nocturnal, hypermotor activity with asymmetric limb involvement, making it the correct localization.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Epilepsy",
    "explanation": "The semiology of epileptic seizures can provide excellent localizing clues. In this case, the patient\u2019s seizures are brief, have an abrupt onset, and occur predominantly at night. The presence of hyperkinetic, asymmetrical limb extension suggests involvement of a motor area. Seizures originating in the Supplementary Motor Area (SMA) tend to be brief and involve hypermotor activity due to the region\u2019s role in planning and initiating movements. The asymmetric limb extension (often described as a 'figure-of-4' or tonic posturing) is consistent with contralateral propagation of the ictal activity from the SMA. Clinically, SMA seizures are characterized by abrupt onset, brief duration (often less than a minute), and prominent motor features that may include asymmetric limb movements. The fact that these events occur at night further supports a frontal lobe origin, particularly from the SMA rather than the temporal or dorsolateral frontal areas. Video-EEG monitoring is essential for capturing the ictal semiology and confirming SMA involvement. Differential diagnoses include seizures from the frontal operculum (which typically display oropharyngeal automatisms), dorsolateral frontal seizures (which have more complex but less well\u2010defined motor patterns), and mesial temporal lobe seizures (which usually have prominent auras and automatisms without marked hyperkinesis). First-line management typically involves optimizing antiepileptic drug therapy (such as with levetiracetam, lamotrigine, or carbamazepine). For drug-refractory cases, surgical evaluation may be warranted. In managing patients who are pregnant or lactating, seizure control is paramount, and drug selection is guided by safety profiles and teratogenic risks. Option A: Frontal operculum seizures are usually characterized by speech arrest and orofacial automatisms, not the hyperkinetic asymmetric limb extension described. Option B: Dorsolateral frontal seizures tend to produce more complex, less stereotyped motor behaviors. Option C: Mesial temporal lobe seizures typically present with auras and automatisms rather than abrupt hyperkinetic movement. Option D: The Supplementary Motor Area (SMA) best explains the brief, nocturnal, hypermotor activity with asymmetric limb involvement, making it the correct localization. 1. SMA seizures typically occur at night, are very brief, and present with hypermotor features. 2. Detailed video-EEG analysis is vital to differentiate between subtypes of frontal lobe epilepsies based on semiology. Current research emphasizes the role of high-resolution EEG and advanced imaging techniques in reliably localizing seizures within the frontal lobe. Guidelines stress the importance of correlating clinical semiology with electrophysiologic data to plan appropriate management.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "long senario 18 years female pt with seizure and take only one EAD, found in the bed die\nWhat is the risk of SUDEP?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Epilepsy",
    "explanation": "Sudden Unexpected Death in Epilepsy (SUDEP) is a tragic outcome in epilepsy patients but is linked more to seizure frequency and poor control than to the number of medications being taken. SUDEP is thought to occur due to a combination of peri-ictal cardiac and respiratory dysregulation, typically in patients with frequent generalized tonic-clonic seizures. Good seizure control, often achieved by monotherapy when possible, is associated with a lower risk of SUDEP. In the scenario described, the patient was on a single AED, which would theoretically indicate better-controlled epilepsy relative to patients requiring polytherapy or those with refractory seizures. Studies have consistently shown that SUDEP risk is highest in patients with uncontrolled, frequent, or generalized seizures, not simply based on the number of medications used. Assessing SUDEP risk involves evaluating seizure frequency, adherence to medications, and other comorbidities. The differential risk factors include nocturnal seizures, frequent generalized tonic-clonic events, and poor compliance rather than the use of monotherapy. The primary strategy for reducing SUDEP risk is optimal seizure control using the fewest possible medications. Patient and caregiver education, adherence to treatment, and addressing modifiable risk factors are essential. In pregnant and lactating women, it is even more crucial to balance seizure control with potential medication effects, ensuring close monitoring and perhaps adjusting doses to maintain a stable therapeutic level. The only option provided relates to monotherapy. However, since being on one medication is not a risk factor for SUDEP \u2013 in fact, monotherapy is generally associated with a lower risk compared with polytherapy or uncontrolled seizures \u2013 the correct answer is effectively 'None' (i.e., the medication factor described is not a risk factor). 1. SUDEP risk is most strongly linked to frequent generalized tonic-clonic seizures, not the number of antiepileptic medications. 2. Effective seizure control, particularly with monotherapy, is one of the best strategies to reduce the risk of SUDEP. Recent guidelines and systematic reviews continue to highlight that SUDEP risk is minimized by achieving sustained seizure control. Advances in understanding peri-ictal autonomic dysfunction have further clarified that medication adherence and targeting seizure reduction are central to SUDEP prevention.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of Lennox Gastaut epilepsy what you will give??",
    "option_a": "Carbamazepine",
    "option_b": "Depakine",
    "option_c": "Keppra",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Lennox\u2010Gastaut syndrome (LGS) is a severe childhood epileptic encephalopathy characterized by multiple seizure types (e.g., tonic, atonic, atypical absence), abnormal interictal EEG patterns (slow spike\u2010wave complexes), and varying degrees of cognitive impairment. Management focuses on reducing seizure frequency and improving quality of life. LGS arises from widespread cortical dysfunction with multiple etiologies including genetic mutations, structural brain abnormalities, and perinatal insults. The underlying network dysfunction leads to mixed seizure types and a characteristic slow spike\u2010wave EEG pattern. Recent studies have emphasized the importance of early and aggressive management to limit neurodevelopmental deterioration. Patients typically present between 3 and 5 years of age with polymorphic seizure types, notably tonic seizures frequently occurring during sleep that may lead to falls (drop attacks). Cognitive and behavioral impairments are common. The EEG usually shows slow (<2.5 Hz) generalized spike\u2010wave discharges and bursts of fast activity. Diagnosis is made on clinical grounds supported by EEG findings. Differential diagnoses include other childhood epileptic encephalopathies such as West syndrome in infants or Dravet syndrome. MRI is used to identify any underlying structural lesion. A detailed history, developmental assessment, and EEG are critical for distinguishing LGS from other refractory epilepsy syndromes. First-line treatment for LGS typically involves broad-spectrum antiseizure medications. Valproate (Depakine) is considered one of the primary agents. Other options include lamotrigine, topiramate, and clobazam as adjunctive therapy. For women of childbearing potential, careful consideration is necessary since valproate carries a high teratogenic risk; alternatives should be considered in pregnancy and lactation, with counseling and dose adjustments as per current guidelines. In refractory cases, ketogenic diet, surgical options, or vagal nerve stimulation may be considered. Option A (Carbamazepine) is avoided in LGS because sodium channel blockers can exacerbate certain seizure types. Option B (Depakine) \u2013 representing valproate \u2013 is a recommended first-line therapy, making it the correct answer. Option C (Keppra) may have a role as adjunctive therapy in some cases but isn\u2019t typically used as monotherapy in LGS. Option D is not provided. 1) Valproate remains a cornerstone in the management of LGS but must be used with caution in women of childbearing potential due to high teratogenicity. 2) Avoid sodium channel blockers such as carbamazepine in LGS as they may worsen seizure control. 3) Multimodal therapy is often required due to the refractory nature of LGS. Recent guidelines and studies support early management with valproate while emphasizing the need for individualized and sometimes multimodal treatment approaches. Research is ongoing into newer therapies and non-pharmacologic options (e.g., dietary or surgical interventions) with the aim of improving neurodevelopmental outcomes.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Normal response of hyperventilation?",
    "option_a": "Generalized delta wave",
    "option_b": "Anterior theta/delta wave",
    "option_c": "(Keppra) may have a role as adjunctive therapy in some cases but isn\u2019t typically used as monotherapy in LGS. Option D is not provided.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Lennox\u2010Gastaut syndrome (LGS) is a severe childhood epileptic encephalopathy characterized by multiple seizure types (e.g., tonic, atonic, atypical absence), abnormal interictal EEG patterns (slow spike\u2010wave complexes), and varying degrees of cognitive impairment. Management focuses on reducing seizure frequency and improving quality of life. LGS arises from widespread cortical dysfunction with multiple etiologies including genetic mutations, structural brain abnormalities, and perinatal insults. The underlying network dysfunction leads to mixed seizure types and a characteristic slow spike\u2010wave EEG pattern. Recent studies have emphasized the importance of early and aggressive management to limit neurodevelopmental deterioration. Patients typically present between 3 and 5 years of age with polymorphic seizure types, notably tonic seizures frequently occurring during sleep that may lead to falls (drop attacks). Cognitive and behavioral impairments are common. The EEG usually shows slow (<2.5 Hz) generalized spike\u2010wave discharges and bursts of fast activity. Diagnosis is made on clinical grounds supported by EEG findings. Differential diagnoses include other childhood epileptic encephalopathies such as West syndrome in infants or Dravet syndrome. MRI is used to identify any underlying structural lesion. A detailed history, developmental assessment, and EEG are critical for distinguishing LGS from other refractory epilepsy syndromes. First-line treatment for LGS typically involves broad-spectrum antiseizure medications. Valproate (Depakine) is considered one of the primary agents. Other options include lamotrigine, topiramate, and clobazam as adjunctive therapy. For women of childbearing potential, careful consideration is necessary since valproate carries a high teratogenic risk; alternatives should be considered in pregnancy and lactation, with counseling and dose adjustments as per current guidelines. In refractory cases, ketogenic diet, surgical options, or vagal nerve stimulation may be considered. Option A (Carbamazepine) is avoided in LGS because sodium channel blockers can exacerbate certain seizure types. Option B (Depakine) \u2013 representing valproate \u2013 is a recommended first-line therapy, making it the correct answer. Option C (Keppra) may have a role as adjunctive therapy in some cases but isn\u2019t typically used as monotherapy in LGS. Option D is not provided. 1) Valproate remains a cornerstone in the management of LGS but must be used with caution in women of childbearing potential due to high teratogenicity. 2) Avoid sodium channel blockers such as carbamazepine in LGS as they may worsen seizure control. 3) Multimodal therapy is often required due to the refractory nature of LGS. Recent guidelines and studies support early management with valproate while emphasizing the need for individualized and sometimes multimodal treatment approaches. Research is ongoing into newer therapies and non-pharmacologic options (e.g., dietary or surgical interventions) with the aim of improving neurodevelopmental outcomes.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Long scenario that patient presented to ER with history of 3 unprovoked seizures all labs is normal, and now she returns to baseline (they did not mention if it's within 24 hrs or no). What you will do?",
    "option_a": "Give AED",
    "option_b": "Don't give AED, OPD with MRI and EEG",
    "option_c": "Give AED and discharge with OPD / EEG and MRI",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Lennox\u2010Gastaut syndrome (LGS) is a severe childhood epileptic encephalopathy characterized by multiple seizure types (e.g., tonic, atonic, atypical absence), abnormal interictal EEG patterns (slow spike\u2010wave complexes), and varying degrees of cognitive impairment. Management focuses on reducing seizure frequency and improving quality of life. LGS arises from widespread cortical dysfunction with multiple etiologies including genetic mutations, structural brain abnormalities, and perinatal insults. The underlying network dysfunction leads to mixed seizure types and a characteristic slow spike\u2010wave EEG pattern. Recent studies have emphasized the importance of early and aggressive management to limit neurodevelopmental deterioration. Patients typically present between 3 and 5 years of age with polymorphic seizure types, notably tonic seizures frequently occurring during sleep that may lead to falls (drop attacks). Cognitive and behavioral impairments are common. The EEG usually shows slow (<2.5 Hz) generalized spike\u2010wave discharges and bursts of fast activity. Diagnosis is made on clinical grounds supported by EEG findings. Differential diagnoses include other childhood epileptic encephalopathies such as West syndrome in infants or Dravet syndrome. MRI is used to identify any underlying structural lesion. A detailed history, developmental assessment, and EEG are critical for distinguishing LGS from other refractory epilepsy syndromes. First-line treatment for LGS typically involves broad-spectrum antiseizure medications. Valproate (Depakine) is considered one of the primary agents. Other options include lamotrigine, topiramate, and clobazam as adjunctive therapy. For women of childbearing potential, careful consideration is necessary since valproate carries a high teratogenic risk; alternatives should be considered in pregnancy and lactation, with counseling and dose adjustments as per current guidelines. In refractory cases, ketogenic diet, surgical options, or vagal nerve stimulation may be considered. Option A (Carbamazepine) is avoided in LGS because sodium channel blockers can exacerbate certain seizure types. Option B (Depakine) \u2013 representing valproate \u2013 is a recommended first-line therapy, making it the correct answer. Option C (Keppra) may have a role as adjunctive therapy in some cases but isn\u2019t typically used as monotherapy in LGS. Option D is not provided. 1) Valproate remains a cornerstone in the management of LGS but must be used with caution in women of childbearing potential due to high teratogenicity. 2) Avoid sodium channel blockers such as carbamazepine in LGS as they may worsen seizure control. 3) Multimodal therapy is often required due to the refractory nature of LGS. Recent guidelines and studies support early management with valproate while emphasizing the need for individualized and sometimes multimodal treatment approaches. Research is ongoing into newer therapies and non-pharmacologic options (e.g., dietary or surgical interventions) with the aim of improving neurodevelopmental outcomes.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Long scenario 6 months old body with typical infantile spasm + developmental delay + EEG SHOWED HYPSARRHYTHMIA?",
    "option_a": "West syndrome",
    "option_b": "Dravet",
    "option_c": "(Keppra) may have a role as adjunctive therapy in some cases but isn\u2019t typically used as monotherapy in LGS. Option D is not provided.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Lennox\u2010Gastaut syndrome (LGS) is a severe childhood epileptic encephalopathy characterized by multiple seizure types (e.g., tonic, atonic, atypical absence), abnormal interictal EEG patterns (slow spike\u2010wave complexes), and varying degrees of cognitive impairment. Management focuses on reducing seizure frequency and improving quality of life. LGS arises from widespread cortical dysfunction with multiple etiologies including genetic mutations, structural brain abnormalities, and perinatal insults. The underlying network dysfunction leads to mixed seizure types and a characteristic slow spike\u2010wave EEG pattern. Recent studies have emphasized the importance of early and aggressive management to limit neurodevelopmental deterioration. Patients typically present between 3 and 5 years of age with polymorphic seizure types, notably tonic seizures frequently occurring during sleep that may lead to falls (drop attacks). Cognitive and behavioral impairments are common. The EEG usually shows slow (<2.5 Hz) generalized spike\u2010wave discharges and bursts of fast activity. Diagnosis is made on clinical grounds supported by EEG findings. Differential diagnoses include other childhood epileptic encephalopathies such as West syndrome in infants or Dravet syndrome. MRI is used to identify any underlying structural lesion. A detailed history, developmental assessment, and EEG are critical for distinguishing LGS from other refractory epilepsy syndromes. First-line treatment for LGS typically involves broad-spectrum antiseizure medications. Valproate (Depakine) is considered one of the primary agents. Other options include lamotrigine, topiramate, and clobazam as adjunctive therapy. For women of childbearing potential, careful consideration is necessary since valproate carries a high teratogenic risk; alternatives should be considered in pregnancy and lactation, with counseling and dose adjustments as per current guidelines. In refractory cases, ketogenic diet, surgical options, or vagal nerve stimulation may be considered. Option A (Carbamazepine) is avoided in LGS because sodium channel blockers can exacerbate certain seizure types. Option B (Depakine) \u2013 representing valproate \u2013 is a recommended first-line therapy, making it the correct answer. Option C (Keppra) may have a role as adjunctive therapy in some cases but isn\u2019t typically used as monotherapy in LGS. Option D is not provided. 1) Valproate remains a cornerstone in the management of LGS but must be used with caution in women of childbearing potential due to high teratogenicity. 2) Avoid sodium channel blockers such as carbamazepine in LGS as they may worsen seizure control. 3) Multimodal therapy is often required due to the refractory nature of LGS. Recent guidelines and studies support early management with valproate while emphasizing the need for individualized and sometimes multimodal treatment approaches. Research is ongoing into newer therapies and non-pharmacologic options (e.g., dietary or surgical interventions) with the aim of improving neurodevelopmental outcomes.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Risk of 2nd seizure in 2 years after first seizure",
    "option_a": "5%",
    "option_b": "30%",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "After a first unprovoked seizure, neurologists focus on estimating the risk of a recurrence over the following years to guide treatment decisions. The recurrence risk helps determine whether to initiate anti\u2010seizure medications immediately. The likelihood of recurrence depends on the presence of an underlying epileptogenic process. Factors such as an abnormal EEG, structural brain lesions, or other neurological deficits indicate that the brain is more susceptible to recurrent discharges, contributing to near 30\u201340% risk over 2 years in many cohorts. Clinicians correlate the 2-year recurrence risk with patient history and ancillary studies. Approximately 30%\u201340% of patients experience a second unprovoked seizure within 2 years. This risk estimate is central to discussions with patients about the benefits and risks of initiating anti-seizure drugs. After a first seizure, evaluation generally includes neuroimaging (MRI) to detect structural abnormalities, an EEG for epileptiform discharges, and a careful review of the history to rule out acute provoked events. Differential diagnoses include metabolic or toxic insults that might cause seizure but do not predict similar recurrence risks. Treatment decisions are guided by the recurrence risk. In patients with a risk around 30\u201340%, some clinicians may opt to begin anti-seizure medication while others favor a wait\u2010and\u2010see approach. For women who are pregnant or of childbearing age, medication choices must prioritize agents with lower teratogenic risks. In lactating mothers, drug excretion into breast milk and potential effects on the infant are also considered. Option A (5%) underestimates the recurrence risk seen in most studies, whereas Option B (30%) fits within the commonly accepted range. Options C and D are not provided, so by elimination and literature support, B is the best answer. \u2022 Approximately one\u2010third of patients experience a recurrence within 2 years of their first seizure. \u2022 Risk stratification is critical for counseling and management decisions. \u2022 EEG and MRI findings are central in refining risk estimates. Recent systematic reviews and large cohort studies continue to support a recurrence risk of approximately 30\u201340% within 2 years of a first unprovoked seizure, underscoring the validity of the 30% approximation in this context.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Focal aware seizure what ASM",
    "option_a": "LCM",
    "option_b": "VPA",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Focal aware seizures (formerly simple partial seizures) originate from a localized area of the cortex and do not impair consciousness. The selection of an appropriate anti\u2010seizure medication is based on seizure type and the targeted mechanism of action. Focal aware seizures occur due to abnormal electrical discharges confined to a specific cortical region. The preservation of awareness occurs because the ictal activity does not extensively involve networks responsible for arousal and higher cognitive functions. Patients typically present with localized sensory, motor, or autonomic symptoms without loss of consciousness. The decision to use a specific anti\u2010seizure medication (ASM) involves balancing efficacy with side effect profiles and, in women of childbearing age, teratogenic risk. Diagnosis is made on the basis of a detailed history and supported by EEG findings that localize the seizure onset. Differential diagnoses include focal impaired awareness seizures and non-epileptic events; video EEG monitoring can help differentiate these conditions. First-line options for focal seizures include carbamazepine, lamotrigine, levetiracetam, and lacosamide. Lacosamide (LCM) is FDA-approved for partial-onset seizures and is an effective, well-tolerated choice with a favorable interaction profile. For pregnant patients or those planning pregnancy, ASMs with lower teratogenic risk should be preferred, and serum levels should be monitored closely during pregnancy and lactation. Option A (Lacosamide) is appropriate given its efficacy in focal seizures and safety profile. Option B (Valproic acid) is a broad-spectrum agent but carries a higher risk of teratogenicity and is generally less favored for focal aware seizures in women of reproductive potential. Options C and D are not provided. \u2022 Lacosamide\u2019s mechanism involves enhancing slow inactivation of voltage\u2010gated sodium channels. \u2022 It is well-tolerated and has become an increasingly popular choice for focal seizures. \u2022 Always consider potential teratogenic effects when choosing an ASM for women. Recent guidelines and clinical trials have validated lacosamide as a safe and effective first-line option for focal seizures, with research supporting its favorable pharmacokinetics and side effect profile compared to older agents.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Mesial temporal sclerosis, what is true",
    "option_a": "Family history of epilepsy",
    "option_b": "History of febrile seizure",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Mesial temporal sclerosis (MTS) is the most common pathology underlying temporal lobe epilepsy. It is characterized by neuronal loss and gliosis in the hippocampus and related temporal lobe structures. MTS is typically the result of an insult\u2014often during childhood\u2014that triggers prolonged or complex febrile seizures. The resulting excitotoxic injury leads to hippocampal scarring, which becomes an epileptogenic focus. Patients with MTS usually develop drug-resistant temporal lobe epilepsy, frequently exhibiting complex partial seizures. A key historical clue is a history of childhood febrile seizures, particularly prolonged or atypical episodes, which is strongly associated with the later development of MTS. Diagnosis is based on neuroimaging (MRI, which shows hippocampal atrophy and increased T2 signal) and supportive EEG findings localized to the temporal lobe. Differential diagnoses include other causes of temporal lobe epilepsy such as tumors or cortical dysplasias, but the imaging pattern in MTS is usually distinctive. Initial management with ASMs is attempted; however, due to the high rate of drug resistance, many patients eventually require an evaluation for surgical treatment. For pregnant patients, medical management is preferred during gestation with a plan for definitive surgery postpartum, unless seizures become uncontrollable. During lactation, ASM selection should consider minimal excretion into breast milk. Option A (Family history of epilepsy) is not a hallmark of MTS. Option B (History of febrile seizure) is the established risk factor linked to the development of MTS. Options C and D are not provided. \u2022 A history of prolonged febrile seizures in childhood is a major risk factor for MTS. \u2022 MTS is a leading cause of medically refractory temporal lobe epilepsy. \u2022 MRI is the imaging modality of choice for diagnosing MTS. Recent research continues to support the association between early-life complex febrile seizures and MTS, with numerous studies emphasizing the role of excitotoxic injury in hippocampal sclerosis, thereby reinforcing the clinical significance of this historical detail.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Same scenario: what is the treatment?",
    "option_a": "Benzodiazepine",
    "option_b": "",
    "option_c": "(marked answer) is assumed to represent surgical resection (e.g., anterior temporal lobectomy), which is the recommended treatment for refractory MTS. Options B and D are not provided.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "In patients with mesial temporal sclerosis who experience medically refractory temporal lobe epilepsy, definitive treatment often shifts from medical management to surgical intervention. The structural changes in MTS, including hippocampal neuronal loss and gliosis, create a persistent and drug-resistant epileptogenic focus. This abnormal area frequently does not respond to conventional anti-seizure medications, necessitating removal to prevent ongoing seizure activity. Patients with MTS typically have ongoing seizures despite optimal medical therapy. When these seizures become refractory, the risk of injury, cognitive decline, and decreased quality of life increases, making evaluation for surgical intervention crucial. Patients are thoroughly evaluated using high-resolution MRI and video EEG monitoring to localize the seizure focus. Differential diagnoses for refractory temporal lobe epilepsy include dual pathology (e.g., tumors, dysplasia) or less common extratemporal foci. Comprehensive presurgical work-up is essential. For patients with MTLE due to MTS who fail two appropriate ASM trials, surgical options are recommended. The standard treatment is an anterior temporal lobectomy or selective amygdalohippocampectomy. In patients who are pregnant, surgery is generally deferred until after delivery, and medical management is optimized; however, in select cases with severe intractable seizures, a multidisciplinary team may consider timing issues. During lactation, surgical interventions are usually postponed in favor of optimized medical management to reduce risks. Option A (Benzodiazepine) is appropriate only for acute seizure termination or status epilepticus but not for definitive management of chronic, drug-resistant epilepsy due to MTS. Option C (marked answer) is assumed to represent surgical resection (e.g., anterior temporal lobectomy), which is the recommended treatment for refractory MTS. Options B and D are not provided. \u2022 Surgical resection offers the best chance for seizure freedom in drug-resistant MTLE due to MTS. \u2022 Early surgical evaluation is associated with improved long-term outcomes. \u2022 Multidisciplinary pre-surgical work-up is essential to select the appropriate surgical candidate. Recent guidelines by the American Academy of Neurology and the International League Against Epilepsy support surgical resection as the treatment of choice in medically refractory MTLE, with multiple studies demonstrating significant gains in seizure freedom and quality of life post-surgery.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "MTL Epilepsy what is the pathology responsible for it",
    "option_a": "Increased dentate gating",
    "option_b": "mossy fibers sprouting",
    "option_c": "Neuronal loss",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Mesial Temporal Lobe (MTL) epilepsy is most commonly associated with hippocampal sclerosis, a disorder in which specific structural changes occur in the hippocampus. One of the hallmarks of these changes is the abnormal sprouting of mossy fibers from granule cells in the dentate gyrus, which contributes to the formation of aberrant neural circuits. Hippocampal sclerosis involves selective neuronal loss (notably in areas CA1 and CA4) along with reactive gliosis. As a compensatory (yet maladaptive) response to neuronal loss, mossy fibers sprout into areas they do not normally innervate. This aberrant synaptic reorganization leads to recurrent excitatory circuits that lower the seizure threshold and play a key role in epileptogenesis in MTL epilepsy. Patients with MTL epilepsy often present with focal seizures with impaired awareness, sometimes preceded by an aural or psychic aura. The presence of abnormal mossy fiber sprouting helps explain the persistent, recurrent, and sometimes drug-resistant nature of these seizures. Diagnosis typically involves high-resolution MRI to identify hippocampal sclerosis (e.g., atrophy and T2 hyperintensity) and video-EEG monitoring to correlate clinical events with electrophysiologic findings. Differential diagnoses include neoplastic lesions, encephalitis, and other focal structural lesions, which are usually differentiated by their imaging characteristics and clinical context. Management starts with anti-seizure medications such as levetiracetam and lamotrigine. In drug-resistant cases, patients may be evaluated for surgical resection (e.g., anterior temporal lobectomy). In pregnant or lactating patients, medication selection is further refined to balance seizure control with fetal safety, favoring drugs with lower teratogenic risk (e.g., lamotrigine or levetiracetam) while recognizing that surgery is generally deferred until after delivery unless absolutely necessary. Option A (Increased dentate gating) is not consistent with the known pathophysiology, as dentate gating normally serves to limit excitatory input. Option B (Mossy fiber sprouting) correctly identifies the aberrant reorganization that contributes to circuit hyperexcitability in MTL epilepsy. Option C (Neuronal loss) is also seen in hippocampal sclerosis but is a more generic finding and does not capture the key mechanism of network reorganization driving epileptogenesis. Thus, Option B is the most specifically correct answer. 1) Mossy fiber sprouting is a critical mechanism in the epileptogenic process of hippocampal sclerosis. 2) MTL epilepsy often presents with auras and focal impaired awareness seizures. 3) MRI findings of hippocampal atrophy and signal changes support the diagnosis. Recent studies continue to underscore the role of mossy fiber sprouting in the development of epileptogenic networks within the hippocampus, and research is ongoing into therapies targeting this aberrant plasticity to better control or prevent seizures in MTL epilepsy.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Pregnant lady with Epilepsy on valproic acid and want to change the medication",
    "option_a": "CBZ",
    "option_b": "LTG",
    "option_c": "LEV",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "In women with epilepsy who are pregnant or planning pregnancy, the risk of teratogenicity is a major concern. Valproic acid is known for its high teratogenic risk, leading clinicians to seek safer therapeutic alternatives. Valproic acid interferes with folate metabolism and has been strongly associated with neural tube defects and other congenital malformations. Lamotrigine, by contrast, has a better teratogenic profile and does not significantly increase the risk of major congenital malformations when used appropriately. Women taking valproic acid who become pregnant have a higher risk of giving birth to children with neural tube defects. Transitioning to a safer alternative like lamotrigine helps mitigate these risks while providing effective seizure control. Before making any medication changes, clinicians should assess the patient\u2019s seizure history, evaluate folate levels, and consider preconception counseling. Regular follow-up and monitoring, including drug level assessments during pregnancy, are essential to ensure both maternal and fetal safety. First-line management for women on valproic acid who plan to become or are pregnant is to transition to a safer antiepileptic drug. Lamotrigine is widely recommended due to its lower teratogenic risk. In the tiered approach, after assessing seizure control, a gradual cross-taper is initiated to minimize the risk of breakthrough seizures. During lactation, lamotrigine is also generally preferred, although its levels should be monitored, as concentrations can change postpartum. Option A (Carbamazepine) also carries teratogenic risks and is not preferred over lamotrigine. Option B (Lamotrigine) is the best choice given its favorable safety profile for both pregnancy and lactation. Option C (Levetiracetam) is considered relatively safe as well; however, lamotrigine has traditionally been the first-line recommendation for women of childbearing age, based on extensive clinical experience and guidelines. 1) Valproic acid has one of the highest teratogenic risks among antiepileptics. 2) Lamotrigine is a preferred alternative in women planning pregnancy due to its lower incidence of congenital malformations. 3) Close monitoring and dose adjustments are vital during pregnancy due to altered drug metabolism. Recent guidelines from the International League Against Epilepsy (ILAE) and the American Academy of Neurology (AAN) continue to endorse lamotrigine as a first-line alternative in pregnant women with epilepsy. Emerging data supporting levetiracetam\u2019s safety are also promising, although lamotrigine remains a well-established choice.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with seizure including myoclonic what to give;",
    "option_a": "Lacosomide",
    "option_b": "VPA",
    "option_c": "LEV",
    "option_d": "Topiramate",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Myoclonic seizures are a defining feature of certain generalized epilepsy syndromes, such as Juvenile Myoclonic Epilepsy (JME). Effective management requires a broad-spectrum antiepileptic that targets various seizure types, particularly myoclonic jerks. Valproic acid increases gamma-aminobutyric acid (GABA) levels and modulates sodium channel activity, thereby stabilizing neuronal membranes and reducing the propensity for myoclonic and generalized tonic-clonic seizures. Patients with myoclonic seizures often experience sudden, brief muscle jerks, sometimes alongside generalized tonic-clonic seizures. In the context of JME, valproic acid has a proven track record of reducing seizure frequency and intensity. Diagnosis is based on a thorough clinical history and supported by EEG findings that characterize generalized epileptiform discharges. Differential diagnoses include other causes of myoclonus (such as metabolic disturbances or cortical myoclonus), but the classic presentation of JME and age of onset usually help distinguish the condition. For patients with myoclonic seizures, valproic acid is traditionally the first-line treatment due to its broad-spectrum efficacy. However, in women of childbearing potential, the teratogenic risk of valproate necessitates considering alternatives such as levetiracetam or lamotrigine. In non-pregnant populations or male patients, valproate remains highly effective. Option A (Lacosamide) is primarily used for focal seizures, and Option D (Topiramate) is not commonly first-line for myoclonic seizures. Option B (Valproic acid) is correct because it effectively controls myoclonic seizures. Option C (Levetiracetam) is a potential alternative, particularly for women due to teratogenic concerns, but in a general scenario, valproic acid is the standard choice. 1) Valproic acid is highly effective for multiple seizure types in generalized epilepsy, especially myoclonic seizures. 2) Alternatives should be considered for women of childbearing age due to valproate\u2019s teratogenicity. 3) Accurate diagnosis is key, as seizure types dictate the choice of antiepileptic drug. Contemporary studies continue to validate valproic acid's efficacy in treating myoclonic and generalized seizures. Although newer agents like levetiracetam are gaining recognition, valproate remains the benchmark in settings where its use is appropriate and safe.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "A 50-year-old male patient had confusion and delirium without fever, and resolved; the patient mentioned he does not remember what happened in the last two days. The basic workup is normal. What to do next?",
    "option_a": "EEG",
    "option_b": "CT/CTA",
    "option_c": "Urine toxicology",
    "option_d": "CTA head and neck",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "In situations where a patient experiences transient confusion and amnesia, particularly when basic workup (including imaging and labs) is unrevealing, a seizure, especially a focal or subclinical one, should be strongly considered. EEG is the tool of choice to detect underlying epileptiform activity. A seizure, especially one originating in the temporal lobe, can induce a postictal state characterized by confusion, delirium, and memory loss. This state reflects transient neuronal dysfunction following the abnormal electrical discharge. The patient\u2019s episode of confusion and subsequent amnesia, coupled with a normal CT/CTA and laboratory evaluation, suggests a postictal phenomenon rather than an acute structural or metabolic disorder. This makes an electroencephalogram (EEG) the appropriate next diagnostic step. After ruling out acute causes (e.g., stroke, intoxication, metabolic disturbances), an EEG is indicated to assess for interictal epileptiform discharges or postictal slowing. The differential diagnosis includes transient global amnesia (TGA), but TGA typically presents with isolated amnesia without the preceding delirium seen in seizures. Following an EEG evaluation, if epileptiform discharges are identified, initiation of an appropriate antiepileptic medication may be warranted. If the EEG is normal yet clinical suspicion remains high, further prolonged or ambulatory EEG monitoring might be necessary. In any case, management should be tailored to the patient\u2019s overall clinical picture, with adjustments for comorbidities and potential polypharmacy in older adults. Option A (EEG) is the correct next step to evaluate for seizure activity or postictal changes. Option B (CT/CTA) is less useful given the normal initial workup. Option C (Urine toxicology) is indicated only if there is suspicion of substance-induced events, which is not suggested here. Option D (CTA head and neck) is unnecessary in the absence of focal neurological deficits or vascular concerns. 1) EEG is an invaluable tool for diagnosing seizures, particularly in patients with transient neurological deficits and a normal imaging workup. 2) Postictal confusion and amnesia are common and can be transient, emphasizing the need for careful history-taking. 3) Normal initial imaging does not exclude the diagnosis of a seizure. Recent guidelines from neurology societies reinforce the role of EEG as the next diagnostic step in patients with unexplained transient confusion or amnesia, especially when clinical history suggests a possible seizure. Advances in EEG technology, including prolonged monitoring, have improved detection of subtle epileptiform activity.",
    "exam_year": "2023",
    "exam_type": "Part II"
  }
]